News Novo Nordisk files Wegovy product that claimed rapid voucher Novo Nordisk is using its recently awarded FDA priority voucher on a high-strength version of its obesity drug Wegovy.
News Data sets up phase 3 trials for Novo's amycretin in diabetes Novo Nordisk has decided to move its amycretin into pivotal trials in type 2 diabetes after a phase 2 readout.
News Innovent files high-dose mazdutide for obesity in China Innovent has filed a new high-strength version of its weight-loss drug mazdutide in China, aiming to help people with severe obesity.
News Lilly becomes first $1trn+ pharma company Eli Lilly has become the first pharma group to reach a value of more than $1 trillion, joining a select group populated mainly by tech giants.
News Waltz dances into direct-to-employer sales of obesity drugs Waltz Health is planning to disrupt the weight-loss therapy market in the US with a new direct-to-employer sales channel.
News Advocate slams muted response to UK male health strategy A mental health campaigner has condemned the "stunning silence" from mainstream media in the UK as the first-ever men's health strategy is revealed.
News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
